{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:34:12Z","timestamp":1768592052313,"version":"3.49.0"},"reference-count":94,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3036,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2007.01385.x","type":"journal-article","created":{"date-parts":[[2007,5,11]],"date-time":"2007-05-11T00:12:17Z","timestamp":1178842337000},"page":"999-1014","source":"Crossref","is-referenced-by-count":37,"title":["Long-term complications of antiretroviral therapy: lipoatrophy"],"prefix":"10.1155","volume":"61","author":[{"given":"L.","family":"Waters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2007,5,10]]},"reference":[{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB1|cit1","first-page":"36","article-title":"The impact of antiretroviral therapy on AIDS and survival","volume":"11","author":"Lundgren","year":"2006","journal-title":"J HIV Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1086\/324744","article-title":"Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus","volume":"34","author":"Wanke","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dki165","article-title":"Current perspectives on HIV-associated lipodystrophy syndrome","volume":"56","author":"Milinkovic","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","article-title":"An objective case definition of lipodystrophy in HIV-infected adults: a case-control study","volume":"361","author":"Carr","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/135965350300800306","article-title":"Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor","volume":"8","author":"Domingo","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1097\/00002030-199910220-00035","article-title":"The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat distribution in men with HIV infection","volume":"40","author":"Bacchetti","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/135965350100600102","article-title":"Antiretroviral therapy and the lipodystrophy syndrome","volume":"6","author":"John","year":"2001","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200411050-00005","article-title":"The effects of HIV protease inhibitors atazanavir and lopinavir\/ritonavir on insulin sensitivity in HIV-seronegative healthy adults","volume":"18","author":"Noor","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh013","article-title":"Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients","volume":"53","author":"Calza","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1086\/430379","article-title":"Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women","volume":"40","author":"Jacobson","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB21|cit21","first-page":"199","article-title":"Lipodystrophy and dyslipidemia among patients taking first-line, world health organization-recommended highly active antiretroviral therapy regimens in western India","volume":"39","author":"Pujari","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl. 2","key":"10.1111\/j.1742-1241.2007.01385.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"M3","DOI":"10.1177\/135965350501002S02","article-title":"Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy","volume":"10","author":"Cote","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/135965350300800614","article-title":"Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level","volume":"8","author":"Nolan","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB24|cit24","first-page":"263","article-title":"Increased adipocyte apoptosis in lipoatrophy improves within 48\u2003weeks of switching patient therapy from stavudine to abacavir or zidovudine","volume":"38","author":"Cherry","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB25|cit25","first-page":"L4","article-title":"Assessing the contribution of ART, HIV and host factors to adipose tissue changes occurring in HIV-infected individuals: risk profile for lipoatrophy","volume":"10","author":"Hammond","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0140-6736(02)08094-7","article-title":"Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance","volume":"359","author":"Bastard","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/135965350400900609","article-title":"Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms","volume":"9","author":"Nolan","year":"2004","journal-title":"Antivir Ther"},{"issue":"Suppl. 2","key":"10.1111\/j.1742-1241.2007.01385.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"M83","DOI":"10.1177\/135965350501002S09","article-title":"Mitochondrial \u2018DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals","volume":"10","author":"Gerschenson","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/135965350400900206","article-title":"Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations","volume":"9","author":"Gourgeon","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4049\/jimmunol.144.2.480","article-title":"Infection with HIV is associated with elevated IL-6 levels and production","volume":"144","author":"Breen","year":"1990","journal-title":"J Immunol"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/clin.1997.4364","article-title":"Relationship of plasma HIV-RNA levels and levels of TNF-alpha and immune activation products in HIV infection","volume":"84","author":"Salazar-Gonzalez","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"E261","DOI":"10.1152\/ajpendo.00056.2003","article-title":"Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy","volume":"286","author":"Johnson","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/00002030-200307040-00011","article-title":"Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy","volume":"17","author":"Vigouroux","year":"2003","journal-title":"AIDS"},{"issue":"Suppl. 2","key":"10.1111\/j.1742-1241.2007.01385.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"M73","DOI":"10.1177\/135965350501002S08","article-title":"Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings","volume":"10","author":"Miro","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB37|cit37","first-page":"L11","article-title":"Differential effects of nucleoside reverse transcriptase inhibitor (NRTI) regimens on adipocyte mitochondrial DNA depletion in HIV-infected patients","volume":"9","author":"Hammond","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB38|cit38","first-page":"L6","article-title":"Assessing the risk of adipose tissue mitochondrial toxicity in HIV-infected individuals on contemporary NRTI regimens","volume":"11","author":"Hammond","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB39|cit39","first-page":"L18","article-title":"Prospective evaluation of regional body composition in antiretroviral naive subjects randomized to receive zidovudine\u2003+\u2003lamivudine or didanosine\u2003+\u2003stavudine combined with nelfinavir, efavirenz or both: A5005s, a substudy of ACTG 384","volume":"7","author":"Dube","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/135965350400900317","article-title":"Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy","volume":"9","author":"Van Der Valk","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB41|cit41","first-page":"L5","article-title":"DEXA outcomes in antiretroviral-na\u00efve subjects receiving nelfinavir or efavirenz or both plus dual nucleosides: long-term as-treated results from A5005s","volume":"11","author":"Dube","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB42|cit42","unstructured":"Jemsek JG Arathoon E Arlotti M et\u00a0al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.aids.0000131332.30548.92","article-title":"SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir\/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients","volume":"18","author":"Gathe","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB45|cit45","first-page":"L32","article-title":"The proportion of patients reporting body fat redistribution was unchanged between week 48 and week 120 in subjects receiving fosamprenavir\/ritonavir in study APV 30005","volume":"9","author":"Walmsley","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB47|cit47","volume-title":"Program and Abstracts of the XVI International AIDS Conference","author":"Gallant","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/sti.79.2.137","article-title":"A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals","volume":"79","author":"Power","year":"2003","journal-title":"Sex Transm Infect"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB49|cit49","first-page":"546","article-title":"Psychosocial impact of the lipodystrophy syndrome in HIV infection","volume":"10","author":"Collins","year":"2000","journal-title":"AIDS Read"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB50|cit50","first-page":"369","article-title":"Relationship between lipoatrophy and quality of life","volume":"15","author":"Echavez","year":"2005","journal-title":"AIDS Read"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB51|cit51","volume-title":"3rd IAS Conference on HIV Pathogenesis and Treatment","author":"Marin","year":"2005"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1310\/W1QF-C9X9-9PFT-88JK","article-title":"Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART","volume":"4","author":"Guaralidi","year":"2003","journal-title":"HIV Clin Trials"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB53|cit53","unstructured":"US Department of Health and Human Services Adherence Supplement to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 29 October 2004 http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL_AdherenceSup.pdf 2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/00002030-200110190-00012","article-title":"Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome","volume":"15","author":"Kosmiski","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/368185","article-title":"Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution","volume":"36","author":"Hadigan","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00126334-200012010-00004","article-title":"Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy","volume":"25","author":"Mynarcik","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB58|cit58","volume-title":"Program and Abstracts of the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","author":"Ranade","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","volume":"19","author":"Dube","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB60|cit60","volume-title":"Program and Abstracts of the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","author":"Calmy","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB61|cit61","volume-title":"XV International AIDS Conference","author":"Boyd","year":"2004"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2\u2003years after switching from a thymidine analogue to abacavir: the MITOX Extension Study","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","article-title":"An objective case definition of lipodystrophy in HIV-infected adults: a case-control study","volume":"361","author":"Carr","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB65|cit65","volume-title":"3rd IAS Conference on HIV Pathogenesis and Treatment","author":"Moreno","year":"2005"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB66|cit66","volume-title":"12th CROI","author":"Moyle","year":"2005"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB67|cit67","volume-title":"Program and Abstracts of the 10th European AIDS Conference","author":"Moyle","year":"2005"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB68|cit68","volume-title":"Program and Abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment","author":"Benn","year":"2005"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/343050","article-title":"Switching effective antiretroviral therapy: a review","volume":"35","author":"Drechsler","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB71|cit71","volume-title":"Program and Abstracts of the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","author":"Cassetti","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB72|cit72","volume-title":"Program and Abstracts of the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","author":"Madruga","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/504874","article-title":"Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study","volume":"43","author":"Rauch","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB74|cit74","first-page":"L11","article-title":"Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactions","volume":"11","author":"Reeves","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB75|cit75","volume-title":"8th International Congress on Drug Therapy in HIV Infection","author":"Waters","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study","volume":"38","author":"McComsey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/01.aids.0000186019.47297.0d","article-title":"Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study","volume":"19","author":"Mussini","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB78|cit78","volume-title":"Sixteenth International Conference on AIDS","author":"El-Sadr","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB79|cit79","first-page":"L6","article-title":"A six month interruption in HIV-infected patients improves adipose tissue morphology and gene expression (ANRS EP29 Lipostop)","volume":"11","author":"Kim","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/jac\/dki062","article-title":"Therapeutic approaches to combating lipoatrophy: do they work?","volume":"55","author":"Martin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB81|cit81","volume-title":"10th European AIDS Conference","author":"Sutinen","year":"2005"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB83|cit83","volume-title":"13th Conference on Retroviruses and Opportunistic Infections","author":"Slama","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB84|cit84","volume-title":"13th Conference on Retroviruses and Opportunistic Infections","author":"Kohli","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","article-title":"Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio","volume":"21","author":"Mulligan","year":"2007","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-143-5-200509060-00009","article-title":"Comparison of rosiglitazone and metformin for treating HIV lipodystrophy","volume":"143","author":"Van Wijk","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB88|cit88","unstructured":"Macallan DC Mandalia S Panayiotakopoulos G Baldwin C Moyle GJ Comparing the effects of Rosiglitazone, Pravastatin, Recombitant human growth hormone and combinations thereof on HIV-associated lipodystrophy. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27-30 September, 2006 (Abstract)"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB89|cit89","volume-title":"Thirteenth Conference on Retroviruses and Opportunistic Infections","author":"Slamal","year":"2006"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/01.aids.0000222072.37749.5a","article-title":"Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - a randomized, placebo-controlled study","volume":"20","author":"Mallon","year":"2006","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB91|cit91","first-page":"639","article-title":"Management options for facial lipoatrophy","volume":"14","author":"Cofrancesco","year":"2004","journal-title":"AIDS Read"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1468-1293.2006.00342.x","article-title":"Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy","volume":"7","author":"Moyle","year":"2006","journal-title":"HIV Med"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"34S","DOI":"10.1097\/01.prs.0000234847.36020.52","article-title":"Prospective open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability","volume":"118","author":"Silvers","year":"2006","journal-title":"Plast Reconstr Surg"},{"key":"10.1111\/j.1742-1241.2007.01385.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1468-1293.2001.00071.x","article-title":"HIV-associated lipodystrophy","volume":"2","author":"Mallon","year":"2001","journal-title":"HIV Med"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2007.01385.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2007.01385.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T19:40:13Z","timestamp":1683834013000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2007.01385.x"}},"subtitle":["Long-term complications of antiretroviral therapy"],"short-title":[],"issued":{"date-parts":[[2007,5,10]]},"references-count":94,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01385.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5,10]]}}}